Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Sanofi
(NASDAQ:SNY)
Intraday
$49.00
-0.46
[-0.93%]
After-Hours
$49.00
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$49.00
-0.46
[-0.93%]
At close: May 3
$49.00
0
[0.00%]
After Hours: 5:58PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Sanofi Stock (NASDAQ:SNY)
Sanofi Stock (NASDAQ: SNY)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, May 02, 2024
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation
Vandana Singh
-
3 days ago
Beyfortus Real-World Evidence Published In The Lancet Shows 82% Reduction In Infant RSV Hospitalizations
Benzinga Newsdesk
-
3 days ago
Monday, April 29, 2024
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Shanthi Rexaline
-
6 days ago
Friday, April 26, 2024
Sobi Receives Positive CHMP Opinion Recommending Approval Of Efanesoctocog Alfa For Once-Weekly Treatment Of Haemophilia A
Benzinga Newsdesk
-
Apr 26, 2024, 8:06AM
Thursday, April 25, 2024
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
Vandana Singh
-
Apr 25, 2024, 1:58PM
Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday
Avi Kapoor
-
Apr 25, 2024, 10:15AM
Drugmaker Sanofi's Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings
Vandana Singh
-
Apr 25, 2024, 9:47AM
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Shanthi Rexaline
-
Apr 25, 2024, 6:17AM
Sanofi shares are trading higher following better-than-expected Q1 financial results.
Benzinga Newsdesk
-
Apr 25, 2024, 6:05AM
Sanofi Reiterates 2024 Business EPS Guidance, Expects It To Remain Roughly Stable; Applying Average April 2024 Exchange Rates, The Currency Impact Is Estimated To Be Between -5.5% And -6.5%
Benzinga Newsdesk
-
Apr 25, 2024, 1:42AM
Sanofi Q1 2024 Adj EPS $0.97 Beats $0.94 Estimate, Sales $11.364B Beat $11.044B Estimate
Benzinga Newsdesk
-
Apr 25, 2024, 1:37AM
Tuesday, April 23, 2024
Sanofi's Rilzabrutinib LUNA 3 Phase 3 Study Met Primary Endpoint In Immune Thrombocytopenia
Benzinga Newsdesk
-
Apr 23, 2024, 1:41AM
Monday, April 22, 2024
Sanofi To Pay $100M To Settle Zantac Cancer Lawsuits
Benzinga Newsdesk
-
Apr 22, 2024, 10:31AM
Sunday, April 21, 2024
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Shanthi Rexaline
-
Apr 21, 2024, 5:45PM
Wednesday, April 17, 2024
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Vandana Singh
-
Apr 17, 2024, 2:39PM
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years
Vandana Singh
-
Apr 17, 2024, 11:48AM
Sanofi's Multiple Sclerosis Antibody Shows Reduction Of Disease Activity
Vandana Singh
-
Apr 17, 2024, 11:37AM
Sanofi's CD40L Antibody: New 48-Week Phase 2 Data Support Frexalimab's Potential For High Sustained Efficacy In Multiple Sclerosis
Benzinga Newsdesk
-
Apr 17, 2024, 2:06AM
Monday, April 15, 2024
Innate Pharma Advances Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing To Phase 2 For Blood Cancer Patients
Benzinga Newsdesk
-
Apr 15, 2024, 1:47AM
Friday, April 12, 2024
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
Vandana Singh
-
Apr 12, 2024, 10:40AM
Wednesday, April 10, 2024
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
Vandana Singh
-
Apr 10, 2024, 2:42PM
Tuesday, April 09, 2024
Nurix Therapeutics Extends Ongoing Research Program With Sanofi For STAT6; Anticipates Nominating A Clinical Candidate Within The First Year Of Extension
Benzinga Newsdesk
-
Apr 9, 2024, 7:01AM
Thursday, April 04, 2024
In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster
Vandana Singh
-
Apr 4, 2024, 9:16AM
Wednesday, April 03, 2024
'Sanofi Agrees To Settle About 5,000 Zantac Cancer Suits In US' - Bloomberg
Benzinga Newsdesk
-
Apr 3, 2024, 4:47PM
Wednesday, March 27, 2024
What's Going On European Pharma Giant AstraZeneca Stock On Wednesday?
Vandana Singh
-
Mar 27, 2024, 1:42PM
How Is The Market Feeling About Sanofi?
Benzinga Insights
-
Mar 27, 2024, 11:45AM
Dr Reddy's Entered Into Exclusive Distribution Partnership With Sanofi Healthcare India
Charles Gross
-
Mar 27, 2024, 6:10AM
Tuesday, March 26, 2024
Krispy Kreme-McDonald's Deal Spikes Insulin Stock Interest: 'We're About To Cash In On The Aftermath'
Surbhi Jain
-
Mar 26, 2024, 3:19PM
Friday, March 15, 2024
'PE Firms Eye €7.5 Billion Leveraged Financing For Sanofi Unit; Consumer-Health Unit Could Be One Of Biggest Recent LBOs; CD&R Among Private Equity Firms Looking At Consumer Unit' - Bloomberg News
Benzinga Newsdesk
-
Mar 15, 2024, 12:03PM
Monday, March 11, 2024
Sanofi Says Results From Part 2 Of Amlitelimab Phase 2B Study STREAM-AD Showed Sustained Improvement Of Signs And Symptoms For 28 Weeks In Adults With Moderate To Severe Atopic Dermatitis
Benzinga Newsdesk
-
Mar 11, 2024, 5:44AM
Friday, March 08, 2024
(SNY) - Analyzing Sanofi's Short Interest
Benzinga Insights
-
Mar 8, 2024, 11:15AM
Wednesday, February 28, 2024
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
Stjepan Kalinic
-
Feb 28, 2024, 2:43PM
Monday, February 26, 2024
Peru To Declare Emergency In Parts Of Country For Increase In Dengue Cases
Benzinga Newsdesk
-
Feb 26, 2024, 12:55PM
Reported Saturday, Sanofi's Rilzabrutinib Phase 2 Results Demonstrate Rapidly Reduced Itch Severity And Significantly Improved Disease Activity In Adults With Chronic Spontaneous Urticaria
Benzinga Newsdesk
-
Feb 26, 2024, 3:28AM
Friday, February 23, 2024
Regeneron Pharmaceuticals And Sanofi Announce That Dupixent® sBLA Has Been Accepted For FDA Priority Review For Treatment of COPD With Type 2 Inflammation
Benzinga Newsdesk
-
Feb 23, 2024, 1:40AM
Tuesday, February 20, 2024
Teva Presents New Data Supporting Safety, Tolerability And Target Engagement Of Anti-TL1A Antibody At The 2024 ECCO Annual Meeting
Benzinga Newsdesk
-
Feb 20, 2024, 8:55AM
Friday, February 16, 2024
Denali Therapeutics Was Informed By Its Partner Sanofi That The Phase 2 HIMALAYA Study Evaluating SAR443820/DNL788 In Participants With Amyotrophic Lateral Sclerosis Did Not Meet The Primary Endpoint Of Change In Als Functional Rating Scale-Revised - 8K
Benzinga Newsdesk
-
Feb 16, 2024, 8:07AM
Regeneron And Sanofi Announce Japan First In The World To Approve Dupixent® For Chronic Spontaneous Urticaria
Benzinga Newsdesk
-
Feb 16, 2024, 2:14AM
Thursday, February 08, 2024
What's Going On With Eli Lilly Stock Thursday?
Vandana Singh
-
Feb 8, 2024, 10:36AM
Monday, February 05, 2024
CytoReason's AI-Driven Disease Model Platform Trusted By 5 Top 10 Pharma Companies Harnesses Big Data To Speed Drug Discovery And Development
Meg Flippin
-
Sponsored
Friday, February 02, 2024
Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today?
Vandana Singh
-
Feb 2, 2024, 11:08AM
Thursday, February 01, 2024
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
-
Feb 1, 2024, 1:17PM
Sanofi shares are trading lower after the company reported worse-than-expected Q4 financial results and issued FY24 EPS guidance.
Benzinga Newsdesk
-
Feb 1, 2024, 11:58AM
French Pharma Giant Sanofi's Q4 Earnings Hit By Aubagio Generic Competition, Helped By Flagship Eczema And Newly Launched Hemophilia Drugs
Vandana Singh
-
Feb 1, 2024, 9:24AM
Privately Held-Graviton Bioscience Announces A Strategic Investment From Sanofi, Deal Terms Were Not Disclosed
Benzinga Newsdesk
-
Feb 1, 2024, 7:43AM
Nasdaq Futures Rebound As Traders Eye Apple, Meta, Amazon Earnings: Analyst Flags 'January Barometer' That Bodes Well For The Year
Shanthi Rexaline
-
Feb 1, 2024, 7:27AM
MaxLinear Reports Q4 Results, Joins ING, Wolfspeed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Avi Kapoor
-
Feb 1, 2024, 5:10AM
Earnings Scheduled For February 1, 2024
Benzinga Insights
-
Feb 1, 2024, 5:03AM
Sanofi Appoints François-Xavier Roger As Chief Financial Officer, Effective April 1, 2024
Benzinga Newsdesk
-
Feb 1, 2024, 1:55AM
Sanofi Expects 2024 Business EPS To Remain Roughly Stable; Applying Average January 2024 Exchange Rates, The Currency Is Estimated Between -3.5% To -4.5%
Benzinga Newsdesk
-
Feb 1, 2024, 1:53AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch